

Supplemental Table S3. Actionable mutations found in cfDNA and tumor tissue genotyping in 12 patients who went on to receive matched therapy after having both forms of testing. The mutations that directly led to the selection of matched therapy in each case are indicated in blue text.

Case	Actionable mutation found in cfDNA	Actionable mutation found in tumor tissue genotyping	Matched therapy
1	ESR1, BRCA1	ESR1	SERD
2	ESR1, BRCA2, BRCA1, EGFR, CCND1, PDGFRA, BRAF, KIT, RAF1	None	CDK 4/6 inhibitor
3	ESR1, ERBB2, FGFR1, EGFR	PIK3CA, ATM, BRCA1	SERD then DNA damaging chemotherapy then HER2 directed therapy
4	CDKN2A	PTEN	CDK 4/6 inhibitor
5	PIK3CA, KRAS, ESR1, BRAF, FGFR2, BRCA2, EGFR, KRAS	PIK3CA, ESR1, KRAS, BRCA1	PIK3 inhibitor
6	ESR1	ESR1	SERD
7	CCND1, FGFR1, KRAS, ERBB2	None	CDK 4/6 inhibitor
8	PI3KCA, CCND1	PI3KCA	CDK 4/6 inhibitor
9	PIK3CA, CCND1, EGFR, FGFR1, MET, CDK6, RAF1, BRAF, AR, PDGFRA, KRAS	PIK3CA	CDK 4/6 inhibitor and mTOR inhibitor
10	CCND1, PIK3CA, EGFR	STK11	CDK 4/6 inhibitor and mTOR inhibitor
11	PIK3CA, EGFR	PIK3CA	CDK 4/6 inhibitor and mTOR inhibitor
12	PIK3CA, ESR1, FGFR1	PIK3CA, PTEN	SERD and CDK 4/6 inhibitor